Study of MR-based IGRT for Prostate Cancer

Launched by UNIVERSITY HOSPITAL TUEBINGEN · Mar 24, 2016

Keywords

ClinConnect Summary

This clinical trial is studying a treatment method called MR-based image-guided radiotherapy (IGRT) for men with prostate cancer. This approach uses detailed images from Magnetic Resonance Imaging (MRI) to help doctors precisely target cancer cells during radiation therapy, aiming to improve treatment effectiveness. The trial is currently looking for male participants aged between 65 and 74 who have been diagnosed with prostate cancer and are seeking curative treatment.

To be eligible for the study, participants need to have confirmed prostate cancer and be in generally good health, as measured by the ECOG performance scale (which assesses how well patients can perform daily activities). However, those who have had previous pelvic radiation treatments or serious health issues that could interfere with the study are not eligible. If you join this trial, you can expect to receive a new type of treatment that is designed to be more precise and potentially more effective for prostate cancer, all while being closely monitored by healthcare professionals.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • histologically proven prostate cancer
• • indication for curative treatment
• • ECOG performance scale 0-2
• • Informed consent
• Exclusion Criteria:
• • contraindications for curative treatment
• • age\<18year
• • previous pelvic radiotherapy or prostatic treatment like TURP (transurethral resection of prostate), HIFU (high intensity focused ultrasound)
• • serious comorbidity leading to inability for IGRT (image-guided radiotherapy)
• • contraindications for MRI (Magnetic Resonance Imaging)